NCT06678607View on ClinicalTrials.gov

Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older

PHASE1CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

November 19, 2023

Primary Completion Date

July 28, 2024

Study Completion Date

July 28, 2024

Conditions
Pneumococcal Infectious Disease
Interventions
BIOLOGICAL

Reinovax PCV24 formulation 1

One dose of Reinovax PCV24 formulation 1（0.5mL）

BIOLOGICAL

Reinovax PCV24 formulation 2

One dose of Reinovax PCV24 formulation 1（0.5mL）

BIOLOGICAL

PPSV23

One dose of PPSV23 (0.5 mL) contains 1、2、3、4、5、6B、7F、8、9N、9V、10A、11A、12F、14、15B、17F、18C、19A、19F、20、22F、23F and33F saccharides.

BIOLOGICAL

Placebo

One dose of 0.5 mL placebo is aluminum phosphate adjuvant (aluminum content 0.25mg/dose), sodium chloride, succinic acid, polysorbate 80, and water for injection except for antigen components in 24-valent pneumococcal polysaccharide conjugate vaccine

Trial Locations (1)

Unknown

Zhenjiang Center for Disease Control and Prevention, Zhenjiang

All Listed Sponsors
lead

Shanghai Reinovax Biologics Co.,LTD

INDUSTRY

NCT06678607 - Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older | Biotech Hunter | Biotech Hunter